Renal Cell Cancer, An Issue of Hematology/Oncology Clinics of North America. The Clinics: Internal Medicine Volume 37-5


Book
September 2023
Region: North America
Elsevier Health Science
ID: 5798072

In this issue of Hematology/Oncology Clinics, guest editors Drs. Bradley A. McGregor and Toni K. Choueiri bring their considerable expertise to the topic of Renal Cell Cancer. Top experts in the field cover key topics such as VHL and HIF at the center of renal cell cancer biology; immunobiology and metabolic pathways of renal cell cancer; hereditary renal cell cancer syndromes; the role of the pathologist in renal cell cancer; novel imaging in renal cell cancer; and more.

Contains 18 relevant, practice-oriented topics including the role of surgery in metastatic renal cell cancer; emerging biomarkers in metastatic renal cell cancer; choosing the right treatment for renal cell cancer of variant histology; novel targets in the treatment of renal cell cancer; and more.
Provides in-depth clinical reviews on renal cell cancer, offering actionable insights for clinical practice.
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology
Immunobiology and Metabolic Pathways of Renal Cell Carcinoma
Hereditary Renal Cell Carcinoma Syndromes
The Role of the Pathologist in Renal Cell Carcinoma Management
Insights into Renal Cell Carcinoma with Novel Imaging Approaches
Surgical Management of Localized Disease and Small Renal Masses
Role of Surgery in Metastatic Renal Cell Carcinoma
Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma
Role of Radiation in Treatment of Renal Cell Carcinoma
Prognostic Models in Metastatic Renal Cell Carcinoma
Emerging Biomarkers of Response to Systemic Therapies in Metastatic Clear Cell Renal Cell Carcinoma
Managing First-Line Metastatic Renal Cell Carcinoma: Favorable-Risk Disease
First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy
Renal Cell Carcinoma of Variant Histology: Biology and Therapies
Toxicity Management of Systemic Kidney Cancer Therapies
Management of Brain Metastases in Metastatic Renal Cell Carcinoma
Novel Targeted Therapies for Renal Cell Carcinoma: Building on the Successes of Vascular Endothelial Growth Factor and mTOR Inhibition
Novel Immune Therapies for Renal Cell Carcinoma: Looking Beyond the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte-Associated Protein 4 Axes

Authors

Bradley A. Mcgregor Instructor, Medicine, Harvard Medical School, Clinical Director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute. Toni K. Choueiri Jerome and Nancy Kohlberg Professor, Medicine, Harvard Medical School, Attending Physician, Solid Tumor Oncology, Dana-Farber Cancer Institute, Director, Genitourinary (GU) Oncology Disease Center,Dana-Farber Cancer Institute.

Table of Contents

Authors

Related Topics

Related Products

Immuno-Oncology Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Immuno-oncology Market

Cancers in the Urban Environment. How Malignant Diseases Are Caused and Distributed among the Diverse People and Neighborhoods of a Major Global Metropolis. Edition No. 2

Head and Neck Cancer, An Issue of Hematology/Oncology Clinics of North America. The Clinics: Internal Medicine Volume 35-5

Head and Neck Squamous Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034